iiinova — where your digital self keeps evolving

Paul Klauser

@paulklauser.bsky.social

84 followers 105 following 1 posts

Research Fellow at MSKCC | Developing radiopharmaceuticals to diagnose and treat cancer ☢️

Posts Replies Media

Reposted by Paul Klauser

Caleb Lareau @caleblareau.bsky.social · 05/08/2025

Had a blast this weekend at the Badger Trail Races— super ULTRA mega congrats to @colehoneycutt.bsky.social and @paulklauser.bsky.social on their first 100M finishes!!!! Together, we ran 303.3 miles in under 75 hours, burning 50,000+ calories along the way!

2242

Reposted by Paul Klauser

MSKEducation @mskeducation.bsky.social · 05/06/2025

🎉 Congratulations to #MSKPostdoc Paul Klauser (@paulklauser.bsky.social), mentored by @lewislabmskcc.bsky.social & @caleblareau.bsky.social, on being awarded the prestigious Damon Runyon Quantitative Biology Fellowship! 👏

062

Reposted by Paul Klauser

Damon Runyon Cancer Research Foundation @damonrunyon.org · 04/06/2025

Congratulations to the newest Damon Runyon Quantitative Biology Fellows, five exceptional early-career scientists who are using state-of-the-art computational tools to bring cancer biology into high resolution!

194

Reposted by Paul Klauser

Jason Lewis - Radiochemist @lewislabmskcc.bsky.social · 08/03/2025

The Lewis Lab aka the “Cycletrons” turning out for Stand up to Cancer raising money for treating rare cancers. I was asked to say a few words at the beginning of the ride…. Every penny really does make a difference. @cycleforsurvival.bsky.social @mskcancercenter.bsky.social

072

Reposted by Paul Klauser

Edwin C Pratt @theprattlab.bsky.social · 23/01/2025

Out now at Clin Cancer Research we characterized a new Trop-2 antibody for rapid tumor detection in pancreatic, ovarian, and prostate cancers. We also leveraged pretargeting for rapid, high-capacity imaging. Huge thanks to our collaborators for the amazing work! aacrjournals.org/clincancerre...

aacrjournals.org

Pretargeted Trop-2 immunoPET for rapid, selective detection of pancreatic tumors

Abstract. Purpose: Recent clinical advances with the approval of antibody-drug conjugates targeting Trop-2 such as sacituzumab-govitecan and datopotomab-deruxtecan have garnered tremendous interest fo...

011

Paul Klauser @paulklauser.bsky.social · 16/12/2024

Amazing Day! Couldn't have done it without this stellar group 🤩

030